Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers find novel drug combination approach to speed fight against cancer

Cancer is the leading cause of death in Canada and is responsible for about 30% of all deaths, according to the Canadian Cancer Society. Despite the urgent need for new and effective drugs, it remains extremely difficult to develop anti-cancer therapies in a timely way.

27 Jan 2014

Study demonstrates direct effects of fragmented sleep on tumor growth

Poor-quality sleep marked by frequent awakenings can speed cancer growth, increase tumor aggressiveness and dampen the immune system's ability to control or eradicate early cancers, according to a new study published online January 21, 2014, in the journal Cancer Research.

27 Jan 2014

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU), formerly known as CeeNu® by Bristol-Myers Squibb (BMS), which has officially been removed from the U.S. Food & Drug Administration (FDA) Drug Shortage List.

27 Jan 2014

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

Novocure announced today that the first patient has enrolled in the EF-20 Study, an open label, pilot clinical trial of NovoTTF Therapy plus gemcitabine as first-line therapy for patients with locally advanced and metastatic pancreatic adenocarcinoma.

25 Jan 2014

New drugs for treatment of prostate cancer may not target root cause of the disease

NEW drugs being developed for the treatment of prostate cancer may not be targeting the root cause of the disease, according to research published today (Friday, 24 January 2014) in Cell Death & Differentiation.

25 Jan 2014

Immunotherapy maintenance shows promise in NSCLC

Results from a phase III trial have shown that tecemotide is no more effective than placebo as maintenance therapy in patients with non-small-cell lung cancer.

24 Jan 2014

Researchers reveal how genetic susceptibility plays large role in cancer risk

In laboratory experiments conducted on human cell lines at the Johns Hopkins Kimmel Cancer Center, scientists have shown that people carrying certain mutations in two hereditary cancer genes, BRCA2 and PALB2, may have a higher than usual susceptibility to DNA damage caused by a byproduct of alcohol, called acetaldehyde.

24 Jan 2014

NICE approves MabThera for treating severe forms of GPA and MPA

Today the National Institute for Health and Care Excellence has approved the use of MabThera for two potentially life-threatening auto-immune diseases, GPA and MPA, which result in the inflammation and damage of small blood vessels and frequently involve multiple organs. The two diseases affect over 13,000 people in the UK and are characterised by the breaking down of specific areas of tissue in the body that, if not treated, can lead to organ damage, organ failure and even death.

24 Jan 2014

Rival proteins’ relative expression levels in cancer cells could be biomarkers for prognosis, treatment

Consider two drivers, each with a key that fits the same car. Driver 1 wants simply to turn on the ignition and leave the vehicle idling, ready and waiting to roll. Driver 2 wants to take it on a destructive joy ride.

24 Jan 2014

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College who led a multinational research team.

24 Jan 2014

Scientists develop mathematical model to predict tumor behavior and personalized therapies

Dana-Farber Cancer Institute scientists have developed a mathematical model to predict how a patient's tumor is likely to behave and which of several possible treatments is most likely to be effective.

24 Jan 2014

Etoposide plus cisplatin remains best for limited-stage SCLC

Etoposide plus cisplatin, given alongside accelerated hyperfractionated thoracic radiotherapy, remains the gold standard regimen for patients with limited-stage small-cell lung cancer, Japanese researchers say.

23 Jan 2014

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi's sarcoma.

23 Jan 2014

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia.

23 Jan 2014

Function of stem cells in blood-forming system is regulated by estrogen, says study

Scientists have known for years that stem cells in male and female sexual organs are regulated differently by their respective hormones. In a surprising discovery, researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) and Baylor College of Medicine have found that stem cells in the blood-forming system — which is similar in both sexes — also are regulated differently by hormones, with estrogen proving to be an especially prolific promoter of stem cell self-renewal.

23 Jan 2014

Number of cancer stem cells in tumor might inaccurately estimate tumor's recurrence or progression

New research from The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggests that it may be the quality of cancer stem cells rather than their quantity that leads to better survival in certain patients with oral cancer.

23 Jan 2014

EORTC trial follow-up shows chemo-radiotherapy for patients with rectal cancer does not improve survival

Appearing in Lancet Oncology, long term results of EORTC trial 22921 with 10.4 years median follow-up show that 5-FU (fluorouracil) based adjuvant chemotherapy after preoperative (chemo)-radiotherapy for patients with cT3-resectable T4 M0 rectal cancer does not improve survival or disease-free survival.

23 Jan 2014

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Starpharma today announced that it has received the necessary approvals to commence a phase 1 human clinical trial for its dendrimer-enhanced docetaxel (Taxotere®) chemotherapeutic product, referred to as DEP™-Docetaxel.

23 Jan 2014

Chinese and American researchers introduce new approach to gene therapy

Resistance of tumor cells toward multiple cytostatic drugs is a serious problem in cancer treatment. In the journal Angewandte Chemie, a team of Chinese and American researchers has now introduced a new approach to gene therapy that could counter this problem: The gene that codes for resistance is “silenced” through the use of an ingenious nanocomplex.

22 Jan 2014

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing repeatedly and the disease becoming increasingly resistant to therapy over time.

22 Jan 2014

Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers find novel drug combination approach to speed fight against cancer

Study demonstrates direct effects of fragmented sleep on tumor growth

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

New drugs for treatment of prostate cancer may not target root cause of the disease

Immunotherapy maintenance shows promise in NSCLC

Researchers reveal how genetic susceptibility plays large role in cancer risk

NICE approves MabThera for treating severe forms of GPA and MPA

Rival proteins’ relative expression levels in cancer cells could be biomarkers for prognosis, treatment

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Scientists develop mathematical model to predict tumor behavior and personalized therapies

Etoposide plus cisplatin remains best for limited-stage SCLC

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

Function of stem cells in blood-forming system is regulated by estrogen, says study

Number of cancer stem cells in tumor might inaccurately estimate tumor's recurrence or progression

EORTC trial follow-up shows chemo-radiotherapy for patients with rectal cancer does not improve survival

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Chinese and American researchers introduce new approach to gene therapy

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in